Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xanthohumol + quercetin is a combination of two natural flavonoid compounds: xanthohumol, a prenylated chalcone found primarily in hops, and quercetin, a flavonol widely present in fruits and vegetables. Both are investigated for their anti-inflammatory, antioxidant, antitumor, and metabolic effects. Preclinical studies suggest that both xanthohumol and quercetin independently possess antitumor activities, modulate the gut microbiota, and inhibit oxidative stress by scavenging reactive oxygen species and inhibiting specific enzymes such as aldose reductase, albeit through distinct pathways. The combination does not have an established pharmaceutical name or regulatory status but is explored as a dietary supplement or nutraceutical for colorectal cancer and metabolic syndrome prevention, with emerging evidence suggesting potential synergy in disease-modifying effects when co-administered[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on xanthohumol + quercetin.